ReproNovo announced the first participant has been dosed in the EU Phase 2 trial of RPN-002 for embryo implantation. The update is an early clinical milestone that supports continued progression of the program, but no efficacy, safety, or financial details were provided.
ReproNovo announced the first participant has been dosed in the EU Phase 2 trial of RPN-002 for embryo implantation. The update is an early clinical milestone that supports continued progression of the program, but no efficacy, safety, or financial details were provided.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
